Latest News

Discover how IRIS Registry real-world data turns EHR notes and images into evidence that speeds ophthalmology trials, recruitment, safety studies, and post-approval insights.

FDA accepts vamikibart BLA for UME as data show sustained gains at 1 year; decision July 2027.

FDA advisers review SYD-101, low-dose atropine 0.01% for pediatric myopia, on Oct 30 after a 2025 complete response letter.

Ehsan Rahimy, MD, says most PRIMA serious adverse events occurred early, while vision gains held through 36 months.

Anti-VEGF for ROP is not associated with systemic and neurodevelopmental outcomes.

The evidence for nutrition in eye care is strong for some conditions and thin or absent for others.

A successful premium outcome depends not only on the lens, but also on how well the patient understands what to expect before surgery.

Jacque Duncan, MD, reviews phase 3 DRAGON data on oral tinlarebant for Stargardt disease and its mechanism-related visual effects.

Twice-daily clobetasol 0.05% cleared cells in 26.5% vs 8.6% of patients and pain in 75.1% vs 32.4% after cataract surgery, with no added endothelial cell loss.

A cataract expert discussed if postoperative topical antibiotics add protection after intracameral prophylaxis.

Oral PKC inhibitor darovasertib preserved the eye in 57% of patients facing enucleation and cut projected radiation doses in 70.3% in the phase 2 OptimUM-09 trial.

Noguchi FS formula error was 0.280 D in 486 eyes, LAL piggyback cut residual cylinder to 0.1 D, and Yamane and Gore-Tex fixation showed distinct complication profiles.

In the phase 3 RESTORE-3 trial of 116 Chinese participants, the anti-IGF-1R antibody produced a 60.4% proptosis response rate vs 23.5% with placebo at week 24.